Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06492005
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- NCT06492005 ↗
- Recruiting
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Clinical Study of Efficacy and Safety of 9MW2821Monotherapy or Combined With PD-1 Inhibitor in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- 9MW2821; PD-1 inhibitior
- Arms
- Treatment Cohort A:9MW2821 · Experimental
- Treatment Cohort B:9MW2821+PD-1 inhibitior · Experimental
- Treatment Cohort C:9MW2821 ±PD-1 inhibitior · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Objective Response Rate
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Start
- Jul 26, 2024
- Primary completion
- Jul 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06492005 · updated Jan 10, 2025